课题基金 / 基金详情

BIOLOGICAL TESTING FACILITY - RESEARCH AND DEVELOPMENT OF PRECLINICAL CONTRACEPTIVES

BIOLOGICAL TESTING FACILITY - RESEARCH AND DEVELOPMENT OF PRECLINICAL CONTRACEPTIVES
生物测试设施 - 临床前避孕药的研究和开发
批准号:
10013411
负责人:
TOUFAN PARMAN
金额:
$85.75万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2019
资助国家:
美国
项目状态:
已结题
起止时间:
2019-09-05 至 2020-09-27

项目摘要

项目成果

TOUFAN PARMAN的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Within NICHD/DIPHR, the Contraceptive Development Program (CDP) supports research to develop compounds that can disrupt normal ovulation, sperm production or sperm function for the purpose of developing safe, effective and affordable contraceptives for men or women. The Biological Testing Facility (BTF) is designed to permit rapid evaluation of new compositions-of­ matter, drug formulations, delivery systems, and devices for contraceptive and endocrine activity. The BTF provides overall project management and the capabilities to support all phases of preclinical activities pursuant to development of new contraceptive methods: these include, but are not limited to in vitro and in vivo assays, plasma and microsomal stability studies, absorption, distribution, metabolism, excretion and toxicity (ADMET), pharmacokinetic (PK) and pharmacodynamic (PD) profiling, animal activities and studies, manufacture of active pharmaceutical ingredients (APIs), process and product development, formulation, clinical lot production, preclinical enabling studies and associated tasks leading to the filing of investigational new drug (IND) applications. Compounds formulated by the BTF are prepared under current Good Manufacturing Practices (cGMP) to allow clinical evaluation in the CDP Contraceptive Clinical Trials Network (CCTN). The CCTN investigators have develop protocols to evaluate the drug candidates identified as high priority by the Program. The BTF has been working with the CORs for the Chemical Synthesis Facility and the CCTN and with the investigators in the CCTN to develop and test the appropriate formulations for clinical batches of the candidate compounds. The next clinical study for each candidate drug is dependent on timely receipt of clinical batches to begin the process of recruitment and enrollment. Drugs that are currently in ongoing clinical trials require stability testing of the clinical formulations. The Biological Testing Facility plays a critical role in the drug development mission of the CDP.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
BIOLOGICAL TESTING FACILITY - "RESEARCH AND DEVELOPMENT OF PRECLINICAL CONTRACEPTIVES".
  • 批准号:
    10352181
  • 项目类别:
  • 资助金额:
    $16.06万
  • 财政年份:
    2020
  • 负责人:
    TOUFAN PARMAN
  • 依托单位:
BIOLOGICAL TESTING FACILITY - ADMINISTRATIVE / MANAGEMENT / DATABASE TASK ORDER
  • 批准号:
    10927162
  • 项目类别:
  • 资助金额:
    $52.82万
  • 财政年份:
    2020
  • 负责人:
    TOUFAN PARMAN
  • 依托单位:
BIOLOGICAL TESTING FACILITY - CONTRACEPTIVE RESEARCH AND DEVELOPMENT TASK ORDER
  • 批准号:
    10390264
  • 项目类别:
  • 资助金额:
    $58.76万
  • 财政年份:
    2020
  • 负责人:
    TOUFAN PARMAN
  • 依托单位:
BIOLOGICAL TESTING FACILITY - "RESEARCH AND DEVELOPMENT OF PRECLINICAL CONTRACEPTIVES".
  • 批准号:
    10183638
  • 项目类别:
  • 资助金额:
    $76.68万
  • 财政年份:
    2020
  • 负责人:
    TOUFAN PARMAN
  • 依托单位:
国内基金
海外基金
层出镰刀菌氮代谢调控因子AreA 介导伏马菌素 FB1 生物合成的作用机理
  • 批准号:
    2021JJ40433
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2021
  • 负责人:
    孙磊
  • 依托单位:
寄主诱导梢腐病菌AreA和CYP51基因沉默增强甘蔗抗病性机制解析
  • 批准号:
    32001603
  • 项目类别:
    青年科学基金项目
  • 资助金额:
    24.0万元
  • 批准年份:
    2020
  • 负责人:
    段真珍
  • 依托单位:
AREA国际经济模型的移植.改进和应用
  • 批准号:
    18870435
  • 项目类别:
    面上项目
  • 资助金额:
    2.0万元
  • 批准年份:
    1988
  • 负责人:
    史树中
  • 依托单位: